Evidence map›Paper›PMID 35127398›Full record

ArticleActa pharmaceutica Sinica. B2022

Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy.

Xianbin Ma, Shaochen Yang, Tian Zhang, Shuo Wang, Qichao Yang, Yao Xiao, Xiaoxiao Shi, Peng Xue, Yuejun Kang, Gang Liu and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Advancing brain immunotherapy through functional nanomaterials.Drug delivery and translational research · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Targeted nano-drug delivery systems for tumor immunotherapy.Journal of pharmaceutical analysis · 2026
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Xianbin MaKey Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, School of Materials and Energy & Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Southwest University, Chongqing 400715, China.
Shaochen YangThe State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine, Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
Tian ZhangKey Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, School of Materials and Energy & Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Southwest University, Chongqing 400715, China.
Shuo WangThe State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine, Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
Qichao YangThe State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine, Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
Yao XiaoThe State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine, Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
Xiaoxiao ShiState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China.
Peng XueKey Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, School of Materials and Energy & Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Southwest University, Chongqing 400715, China.
Yuejun KangKey Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, School of Materials and Energy & Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Southwest University, Chongqing 400715, China.
Gang LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China.
Zhi-Jun SunThe State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine, Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
Zhigang XuKey Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, School of Materials and Energy & Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Southwest University, Chongqing 400715, China.
Southwest University · CNWuhan University · CNXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combination of chemotherapy and immunotherapy motivates a potent immune system by triggering immunogenic cell death (ICD), showing great potential in inhibiting tumor growth and improving the immunosuppressive tumor microenvironment (ITM). However, the therapeutic effectiveness has been restricted by inferior drug bioavailability. Herein, we reported a universal bioresponsive doxorubicin (DOX)-based nanogel to achieve tumor-specific co-delivery of drugs. DOX-based mannose nanogels (DM NGs) was designed and choosed as an example to elucidate the mechanism of combined chemo-immunotherapy. As expected, the DM NGs exhibited prominent micellar stability, selective drug release and prolonged survival time, benefited from the enhanced tumor permeability and prolonged blood circulation. We discovered that the DOX delivered by DM NGs could induce powerful anti-tumor immune response facilitated by promoting ICD. Meanwhile, the released mannose from DM NGs was proved as a powerful and synergetic treatment for breast cancer

Indexed as

5-ALA, 5-aminolevulinic acid5-FU, 5-fluorouracilALKP, alkaline phosphataseALT, alanine aminotransferaseAPCs, antigen-presenting cellsAST, aminotransferaseATP, adenosine triphosphateAUC, area under curvesBioresponsiveCe6, chlorin e6ChemotherapyCLSM, confocal laser scanning microscopeCPT-11, irinotecanCRE, creatinineCRT, calreticulinDAMPs, damage-associated molecular patternsDCs, dendritic cellsDDSs, drug delivery systemsDLN, draining lymph nodesDM NGs, doxorubicin-based mannose nanogelDOC, docetaxelDOX, doxorubicinDoxorubicinDTT, d,l-dithiothreitolFCM, flow cytometryFDA, Fluorescein diacetateGEM, gemcitabineGSH, glutathioneHCPT, 10-hydroxy camptothecinHCT, hematocritH&E, hematoxylin-eosinHGB, hemoglobin concentrationHMGB1, high migrating group box 1ICB, immune checkpoint blockadeICD, immunogenic cell deathICG, indocyanine GreenIHC, immunohistochemistryImmunogenic cell deathImmunotherapyirAEs, immune-related adverse eventsITM, immunosuppressive tumor microenvironmentLDH, lactate dehydrogenaseLYM, lymphocyte ratioMAN, mannoseMannoseMCHC, mean corpuscular hemoglobin concentrationMCSs, multicellular spheroidsMFI, mean fluorescence intensityMPV, mean platelet volumeNanogelNGs, nanogelsOXA, oxaliplatinP18, purpurin 18PDI, polydispersity indexPLT, plateletsProdrugPTX, paclitaxelRBC, red blood cell countRDW, variation coefficient of red blood cell distribution widthTAAs, tumor-associated antigensTAM, tumor-associated macrophagesTGF-β, transforming growth factor-βTMA, tissue microarraysTME, tumor microenvironmentUrea, urea nitrogenWBC, white blood cell count

Identifiers

PMID35127398
PMCPMC8800001
OpenAlexW3164939212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.